If our name sounds familiar its probably because youve seen or visited one of our 250 retail stores
On April 1, 2026, the FDA approved Eli Lillys FOUNDAYO (orforglipron) , the second oral GLP-1 approved for obesity, and arguably the one with the more patient-friendly convenience profile
GLP-1 activation is also associated with delayed gastric emptying, another contributing factor to appetite suppression and thus reduced food intake
Saxenda is FDA-approved for chronic weight management and is delivered by injection
Get Started Today If you have any questions or need more information, please give our team a call at (248) 266-5276
A comprehensive program of nutritional and lifestyle counseling is critical to maximize overall efficacy and improve cost-effectiveness of GLP-1s for obesity Long-term Success of GLP-1s Hinges on More Than Just a Prescription A comprehensive program of nutritional and lifestyle counseling is critical to maximize overall efficacy and improve cost-effectiveness of GLP-1s for obesity GLP-1 (glucagon-like peptide-1) therapies can be powerful tools in managing obesity, with patients taking these medications seeing weight reductions of 518% in clinical trials, along with increased metabolism and benefits to their overall heart health
